https://www.mpnallianceaustralia.org.au/wp-content/uploads/2019/02/MPNAA_blood_drop_og.jpg 630 1200 Sue https://www.mpnallianceaustralia.org.au/wp-content/uploads/2019/01/MPNAA_logo_og_image_1200_630-e1643087758121-1030x391.jpg Sue2019-03-01 16:48:132019-03-27 09:18:06Ropegintererfon Alfa 2B Approved for Marketing for Treatment of Polycythemia Vera in the EU
Ropegintererfon Alfa 2B Approved for Marketing for Treatment of Polycythemia Vera in the EU
Ropeginterferon alfa 2b is a longer acting form of pegylated interferon. It has very recently been approved for marketing in the EU for the treatment of Polycythemia Vera under the name “Besremi”. Read the full news announcement here.